| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net loss | NaN | -80,751 | -232,012 |
| Net loss from continuing operations | -76,059 | NaN | NaN |
| Depreciation and amortization | 12,799 | 13,663 | 45,327 |
| Stock-based compensation | 15,853 | 21,027 | 60,519 |
| Goodwill impairment | NaN | 0 | 0 |
| Restructuring related impairment charges | NaN | 0 | NaN |
| Non-cash customer consideration | NaN | 0 | NaN |
| Loss on equity method investments | NaN | 0 | NaN |
| Impairment of right-of-use asset | NaN | NaN | 0 |
| Loss on investments | -939 | NaN | -275 |
| Loss on deconsolidation of subsidiary | NaN | NaN | 0 |
| Loss on investments | NaN | -16,411 | NaN |
| Change in fair value of notes receivable | -6,759 | 11,370 | -5,685 |
| Change in fair value of warrant liabilities | NaN | 0 | 0 |
| Change in fair value of contingent consideration | 0 | 0 | 4,232 |
| Loss on deconsolidation of subsidiaries | NaN | 0 | NaN |
| Impairment of long-lived assets | NaN | 0 | NaN |
| Deferred income tax benefit | NaN | -1,364 | NaN |
| Loss on disposal of equipment | NaN | 0 | NaN |
| Non-cash lease expense | 7,114 | 7,633 | 22,449 |
| Non-cash in-process research and development | NaN | 0 | 0 |
| Accretion of discount on marketable securities | 120 | 888 | 2,502 |
| Other non-cash activity | -185 | -453 | -1,611 |
| Changes in operating assets and liabilities | 242 | 1,818 | -345 |
| Prepaid expenses and other current assets | -5,930 | 5,177 | 70 |
| Operating lease right-of-use assets | 0 | 0 | -3,814 |
| Other non-current assets | -94 | -334 | 38 |
| Accounts payable | NaN | -2,992 | NaN |
| Accounts payable, accrued expenses and other current liabilities | -11,601 | -6,615 | 16,991 |
| Deferred revenue | -2,606 | -5,184 | -27,209 |
| Operating lease liabilities, current and non-current | -4,995 | -9,139 | -18,793 |
| Other non-current liabilities | -758 | 7,004 | 4,459 |
| Net cash used in operating activities - continuing operations | -46,433 | NaN | NaN |
| Net cash used in operating activities - discontinued operations | -253 | NaN | NaN |
| Net cash used in operating activities - continuing operations | -46,686 | -47,678 | -123,381 |
| Deconsolidation of subsidiaries - cash | NaN | 0 | NaN |
| Purchases of marketable debt securities | 83,161 | 16,792 | 401,838 |
| Business acquisitions, net of cash acquired | NaN | 0 | 0 |
| Maturities of marketable debt securities | 108,178 | 85,884 | 73,599 |
| Purchases of notes receivable | NaN | 0 | NaN |
| Proceeds from sale of marketable debt securities | NaN | 25,899 | 0 |
| Proceeds from sales of marketable equity securities | NaN | 0 | NaN |
| Proceeds from sale of equipment | NaN | 574 | 0 |
| Purchases of property and equipment | 1,933 | 5 | 7,660 |
| Other | -48 | 461 | -511 |
| Net cash provided by (used in) investing activities | 23,132 | 95,099 | -335,388 |
| Proceeds from atm offering | NaN | 9,152 | 10,317 |
| Payment of issuance costs related to atm offering | NaN | 985 | 355 |
| Proceeds from exercise of stock options | NaN | 0 | 0 |
| Taxes paid related to net share settlement of equity awards | NaN | 0 | NaN |
| Principal payments on finance leases | 19 | 25 | 329 |
| Contingent consideration payment | NaN | 0 | 0 |
| Other | NaN | NaN | 0 |
| Payment of equity issuance costs and other | NaN | 0 | NaN |
| Net cash used in financing activities | -19 | 8,142 | 9,633 |
| Effect of foreign exchange rates on cash and cash equivalents | -129 | -152 | 353 |
| Net decrease in cash, cash equivalents and restricted cash | -23,702 | 55,411 | -448,783 |
| Cash and cash equivalents at beginning of period | NaN | NaN | 605,743 |
| Cash and cash equivalents at end of period | NaN | NaN | 156,960 |
Ginkgo Bioworks Holdings, Inc. (DNABW)
Ginkgo Bioworks Holdings, Inc. (DNABW)